Hidradenitis Suppurativa Clinical Trials in Chicago, Illinois
8 recruitingChicago, Illinois
Showing 1–8 of 8 trials
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Hidradenitis Suppurativa
Incyte Corporation550 enrolled101 locationsNCT06959225
Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
Rheumatoid Arthritis (RA)Hidradenitis Suppurativa (HS)
Sonoma Biotherapeutics, Inc.36 enrolled10 locationsNCT07123038
Recruiting
Phase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Hidradenitis Suppurativa (HS)
Incyte Corporation600 enrolled316 locationsNCT06855498
Recruiting
Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
AbbVie1,280 enrolled279 locationsNCT06468228
Recruiting
Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Novartis Pharmaceuticals555 enrolled138 locationsNCT06840392
Recruiting
Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Hidradenitis Suppurativa
Novartis Pharmaceuticals555 enrolled145 locationsNCT06799000
Recruiting
Phase 3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Hidradenitis Suppurativa
AbbVie1,328 enrolled285 locationsNCT05889182
Recruiting
Phase 3
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Hidradenitis Suppurativa
MoonLake Immunotherapeutics AG35 enrolled18 locationsNCT06768671